Human immunodeficiency virus type 1 Gag-derived cytotoxic T-lymphocyte epitopes (HIV-1 Gag CTL epitopes)

HIV-1 Gag-derived cytotoxic T-lymphocyte (CTL) epitopes are short peptide sequences derived from the Gag polyprotein (Pr55Gag) of the Human Immunodeficiency Virus type 1. These epitopes are processed by the proteasome and presented on the surface of infected cells by Major Histocompatibility Complex (MHC) class I molecules (UniProt: P04591). They are the primary targets for CD8+ T-cells, which are essential for controlling viral replication during both acute and chronic phases of infection (PubMed: 22532544). Because the Gag protein is highly structural and relatively conserved compared to the envelope proteins, these epitopes are less susceptible to mutational escape, making them central to T-cell-based vaccine strategies (PubMed: 19193794). Clinical research has shown that robust CTL responses against specific Gag epitopes are strongly correlated with lower viral loads and slower disease progression, particularly in "elite controllers" carrying protective HLA alleles like B*57 or B*27 (PubMed: 21048070). Therapeutic interventions, such as DNA, mRNA, and viral vector vaccines (e.g., Pennvax-B, mRNA-1644), aim to expand the breadth and potency of CTLs targeting these epitopes to achieve functional cure or improved viral suppression (ClinicalTrials.gov: NCT04015245). These strategies often focus on conserved regions of Gag to minimize the impact of viral diversity and escape mutations. The success of these therapies depends on the effective presentation of these epitopes across diverse human populations with varying HLA types.

Other names

HIV-1 Gag epitopesGag-specific CD8+ T-cell epitopesPr55Gag epitopesGroup-specific antigen epitopesGag-specific CTL epitopes

Induction of CD8+ T-cell mediated lysis of HIV-infected cells through MHC-I epitope recognition and cytokine-mediated viral suppression.